All webinar times are in Eastern Time except where noted.Convert to your time zone.
Kidney disorders are very common and represent a significant and growing clinical problem. Such disorders are usually diagnosed by identifying a decrease in estimated glomerular filtration rate (eGFR) using a creatinine- or cystatin C-based estimating equation for GFR. The best estimation is obtained by using the average value of a cystatin C-based and a creatinine-based GFR estimating equation. If these two estimates, eGFRcystatin C and eGFRcreatinine, agree, the average value is a very reliable estimate of GFR. However, if eGFRcystatin C is lower than 70% of eGFRcreatinine, in the absence of non-renal factors influencing the levels of cystatin C or creatinine, a previously unidentified kidney disorder, called shrunken pore syndrome (SPS), is present. SPS has a very high mortality and morbidity and this is the case also when measured, or estimated, GFR of the patient is normal, i.e. ≥60ml/min/1.73sqm.
In this webinar, Anders Grubb, MD, PhD, Professor in Clinical Chemistry, Lund University, will first focus on the pros and cons of cystatin C as a kidney marker and then highlight how SPS is diagnosed, the mortality of SPS, the most common death causes associated with SPS, the prevalence of SPS in different populations, and hypotheses concerning its pathophysiology and treatment.
WHAT YOU WILL LEARN
- Learn when and why you should measure cystatin C
- Learn the best way to estimate GFR by using eGFRcystatin C and eGFRcreatinine
- Understand how to diagnose shrunken pore syndrome (SPS)
- Learn about the drastic increase in mortality in patients suffering from SPS
Anders Grubb, MD, PhD
Professor in Clinical Chemistry